Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shanghai Heartcare Medical Technology Corp. Ltd. Class H ( (HK:6609) ) has provided an update.
Shanghai HeartCare Medical Technology Corporation Limited has scheduled a board meeting for March 26, 2026, to review and approve the annual results for the financial year ended December 31, 2025. The board will also consider proposing a final dividend, which could signal the company’s profitability and capital management stance, and may influence investor sentiment and shareholder returns.
The announcement also confirms the current composition of the board, including executive, non-executive and independent non-executive directors, underscoring its established governance structure. This focus on financial disclosure and potential dividend distribution highlights the company’s adherence to regulatory requirements and its ongoing engagement with capital market stakeholders.
The most recent analyst rating on (HK:6609) stock is a Buy with a HK$56.00 price target. To see the full list of analyst forecasts on Shanghai Heartcare Medical Technology Corp. Ltd. Class H stock, see the HK:6609 Stock Forecast page.
More about Shanghai Heartcare Medical Technology Corp. Ltd. Class H
Shanghai HeartCare Medical Technology Corporation Limited is a mainland China-based medical technology company listed in Hong Kong, focusing on cardiovascular-related medical devices and solutions. The company operates through its subsidiaries to develop and commercialize products for heart care, serving hospitals and healthcare providers in the Chinese and broader Asian markets.
Average Trading Volume: 75,794
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.81B
Learn more about 6609 stock on TipRanks’ Stock Analysis page.